Lyell Immunopharma, Inc. LYEL
Set alert
11.04 USD -0.27 -2.34%
At close · Oct 30
11.04 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
10.80 Day range 11.40
7.51 52-week range 38.60
- YTD
- -64.13%
- 1 year
- -33.21%
- Open
- 11.26
- Prev close
- 11.31
- Mkt cap
- 270.54M
- Vol
- 113.26K
- Avg vol
- 151.31K
- EPS
- -12.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.80
- High
- 11.40
- Forward P/E
- -0.73
- Beta
- -0.48
- Short ratio
- 6.15
- Inst. own
- 58.79%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.01
- 200-d avg
- 1.68
- 1y target
- 1.00
2Y chart
Events in this range
- Nov 12, 2024Rating: HC Wainwright & Co. · Neutral → Neutral
- Jun 2, 2025Split: 1 for 20
Signals (72)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 2026 | 2 days ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 1, 2026 | 5 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| SMA: Bearish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 26, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 20, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 11, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| RSI: Overbought | Dec 8, 2025 | 10 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 15, 2025 | 1 year ago |
| RSI: Overbought | Oct 3, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| RSI: Overbought | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 25, 2025 | 1 year ago |
| RSI: Overbought | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 4, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 2, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 6, 2025 | 1 year ago |
| RSI: Overbought | Jul 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 22, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 18, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 26, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 20, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 4, 2025 | 1 year ago |
| RSI: Overbought | Jun 4, 2025 | 1 year ago |
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 13, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 12, 2025 | 1 year ago |
| SMA: Bullish | Feb 20, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
Key statistics
- Market cap
- 179.85M
- Enterprise value
- -210.89M
- Trailing P/E
- 0.00
- Forward P/E
- -0.73
- PEG ratio
- 0.00
- Price / sales
- 2854.84
- Price / book
- 0.30
- EPS (TTM)
- -0.79
- Beta
- -0.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 63.00K
- Revenue growth
- 36.00%
- Free cash flow
- -83.12M
- Total cash
- 440.55M
- Total debt
- 58.58M
- Return on equity
- -33.22%
- Shares outstanding
- 292.16M
- Short % of float
- 4.36%
- 50-day average
- 1.01
- 200-day average
- 1.68
Analyst view
Consensus: hold
Hold
Price target (mean) 1.00
Ratings (0m) 4 0 buy · 3 hold · 1 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.13.
Financials — quick view
LYEL Revenue — quarterly 4.00K
LYEL Net income — quarterly -44.76M
LYEL EPS — quarterly -1.92
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Oct 30, 2024 | B of A Securities | down | Buy | Underperform |
| Oct 28, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 19, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 27, 2024 | B of A Securities | main | Buy | Buy |
| Jun 27, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lyell.com
News
- Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
- Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
- Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
- Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
- This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
- This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
- Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
- Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36
- B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44
- Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts
Your note
Sign in to keep a note on LYEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HILL STEPHEN J | Chief Operating Officer | Stock Award(Grant) | Feb 8, 2024 | 48,928 |
| KLAUSNER RICHARD | Director | Sale | Aug 14, 2023 | 0 |
| LANG MATTHEW | Officer | Stock Award(Grant) | Feb 8, 2024 | 50,000 |
| LEE GARY K | Officer | Stock Award(Grant) | Feb 8, 2024 | 52,700 |
| NEWTON CHARLES W. | Chief Financial Officer | Stock Award(Grant) | Feb 8, 2024 | 48,729 |
| SEELY LYNN | Chief Executive Officer | Stock Award(Grant) | Feb 8, 2024 | 200,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MWG Management Ltd | 6.90% | 20,162,332 | 12.41M | Sep 29, 2024 |
| Orland Properties Ltd. | 5.17% | 15,093,969 | 9.29M | Sep 29, 2024 |
| Blackrock Inc. | 4.71% | 13,747,084 | 8.46M | Sep 29, 2024 |
| Vanguard Group Inc | 3.45% | 10,071,482 | 6.20M | Sep 29, 2024 |
| Foresite Capital Management IV, LLC | 2.85% | 8,325,000 | 5.12M | Sep 29, 2024 |
| Wuxi Apptec Co., Ltd. | 2.53% | 7,390,710 | 4.55M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.99% | 5,817,818 | 3.58M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.85% | 5,398,783 | 3.32M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.47% | 4,286,388 | 2.64M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.86% | 2,522,865 | 1.55M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 1,645,833 | 1.01M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.53% | 1,551,919 | 955.36K | Oct 30, 2024 |